Current Research: Medical Oncology

C100104 -- A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma

The purpose of this study is to compare an investigational drug, CC-5013, to placebo as maintenance therapy for patients who have undergone stem cell transplant (ASCT) for multiple myeloma. The major hypothesis is that CC-5013 maintenance therapy after ASCT for multiple myeloma will prolong the time to disease progression.

Eligibility

You may be eligible for this trial if:

• You are between 18-70 years of age
• You have been diagnosed with multiple myeloma
• You haven’t had a previous bone marrow transplant, peripheral stem cell transplant, or organ transplant.
• It has been at least 4 weeks since chemotherapy, radiation, or surgery.
• You are not pregnant and nursing: These women are excluded because of significant risks to unborn and nursing babies

Trial Sponsor

• Cancer and Leukemia Group B (CALGB)

Project Begin Date

• Aug 2006

Tentative Project End Date

• Dec 2009

Back to Medical Oncology Research

Revised March 30, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .